title: Local delivery versus intracoronary infusion of abciximab in patients with acute coronary syndromes.
abstract: OBJECTIVE
  We investigated whether local abciximab delivery to the site of intracoronary thrombus is more effective than intracoronary bolus infusion in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention and downstream clopidogrel administration.
  
  
  BACKGROUND
  The intracoronary route of administration does not allow an optimal contact between the plaque components and abciximab, which is rapidly washed out by the coronary flow.
  
  
  METHODS
  A total of 50 patients with ACS and a significant lesion in the culprit artery indicative of local thrombosis were randomly assigned to receive local intracoronary delivery of abciximab through a dedicated perfusion catheter or intracoronary infusion through the guiding catheter. The primary end point was the change in thrombus score after angioplasty by optical coherence tomography.
  
  
  RESULTS
  After the intervention, the mean percentage change of the thrombus score was significantly higher among patients of the local delivery group compared with those of the intracoronary infusion group (33.8% vs. 3.9%, p = 0.002). Post-procedural corrected Thrombolysis in Myocardial Infarction frame count was shorter in the local delivery group compared with the intracoronary infusion group (15.3 ± 10.2 vs. 21.1 ± 9.9, p = 0.049). Procedure-related myocardial infarction was observed in 10% and 43% of patients in the local delivery and intracoronary infusion groups, respectively (p = 0.018). At 1 year, MACE were observed in 5.9% and 27.2% of patients in the local delivery and intracoronary infusion groups, respectively (p = 0.046).
  
  
  CONCLUSIONS
  Local intracoronary delivery of abciximab by means of a dedicated perfusion catheter reduces thrombus burden with the potential to improve coronary microcirculation.
authors.affiliation: Interventional Cardiology, San Giovanni Hospital, Rome, Italy. fprati@hsangiovanni.roma.it
authors.forename: Francesco
authors.initials: F
authors.lastname: Prati
authors.forename: Davide
authors.initials: D
authors.lastname: Capodanno
authors.forename: Tomasz
authors.initials: T
authors.lastname: Pawlowski
authors.forename: Vito
authors.initials: V
authors.lastname: Ramazzotti
authors.forename: Mario
authors.initials: M
authors.lastname: Albertucci
authors.forename: Alessio
authors.initials: A
authors.lastname: La Manna
authors.forename: Marilena
authors.initials: M
authors.lastname: Di Salvo
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Gil
authors.forename: Corrado
authors.initials: C
authors.lastname: Tamburino
mesh_terms: D000077284:Abciximab; D054058:Acute Coronary Syndrome / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D017023:Coronary Angiography; D004305:Dose-Response Relationship, Drug; D004333:Drug Administration Routes; D005060:Europe; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage*; D007261:Infusions, Intra-Arterial; D015552:Injections, Intralesional; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab